Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Maris

Showing results (151-160 of 458) with videos related to

Pageof 46
Sort By:
Pediatric Blood & Cancer|June 29, 2010
Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing programChristopher L Morton, Peter J Houghton, E Anders Kolb, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2005
Methionine aminopeptidase 2 inhibition is an effective treatment strategy for neuroblastoma in preclinical modelsMichael J Morowitz, Rosalind Barr, Qun Wang, et al.
Journal of the National Cancer Institute|December 18, 2012
Trans-population analysis of genetic mechanisms of ethnic disparities in neuroblastoma survivalEric R Gamazon, Navin Pinto, Anuar Konkashbaev, et al.
European Journal of Cancer (Oxford, England : 1990)|August 31, 2016
Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with (131)I-metaiodobenzylguanidineKelly E Huibregtse, Kieuhoa T Vo, Steven G DuBois, et al.
Cancer Chemotherapy and Pharmacology|January 2, 2010
Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumorsElizabeth Fox, John M Maris, Susan L Cohn, et al.
Cancer|April 20, 2023
Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcomaKristina A Cole, Heba Ijaz, Lea F Surrey, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 1, 2005
The ETV6-NTRK3 chimeric tyrosine kinase suppresses TGF-beta signaling by inactivating the TGF-beta type II receptorWook Jin, Byung-Chul Kim, Cristina Tognon, et al.
Pediatric Blood & Cancer|February 19, 2010
Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing ProgramPeter J Houghton, Christopher L Morton, Richard Gorlick, et al.
Carcinogenesis|December 11, 2012
Replication of GWAS-identified neuroblastoma risk loci strengthens the role of BARD1 and affirms the cumulative effect of genetic variations on disease susceptibilityMario Capasso, Sharon J Diskin, Francesca Totaro, et al.
Medical and Pediatric Oncology|July 24, 2001
Allelic deletion at chromosome bands 11q14-23 is common in neuroblastomaJ M Maris, C Guo, P S White, et al.
Pageof 46

Showing results (151-160 of 458) with videos related to

Sort By:
Pageof 46
Pediatric Blood & Cancer|June 29, 2010
Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing programChristopher L Morton, Peter J Houghton, E Anders Kolb, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2005
Methionine aminopeptidase 2 inhibition is an effective treatment strategy for neuroblastoma in preclinical modelsMichael J Morowitz, Rosalind Barr, Qun Wang, et al.
Journal of the National Cancer Institute|December 18, 2012
Trans-population analysis of genetic mechanisms of ethnic disparities in neuroblastoma survivalEric R Gamazon, Navin Pinto, Anuar Konkashbaev, et al.
European Journal of Cancer (Oxford, England : 1990)|August 31, 2016
Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with (131)I-metaiodobenzylguanidineKelly E Huibregtse, Kieuhoa T Vo, Steven G DuBois, et al.
Cancer Chemotherapy and Pharmacology|January 2, 2010
Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumorsElizabeth Fox, John M Maris, Susan L Cohn, et al.
Cancer|April 20, 2023
Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcomaKristina A Cole, Heba Ijaz, Lea F Surrey, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 1, 2005
The ETV6-NTRK3 chimeric tyrosine kinase suppresses TGF-beta signaling by inactivating the TGF-beta type II receptorWook Jin, Byung-Chul Kim, Cristina Tognon, et al.
Pediatric Blood & Cancer|February 19, 2010
Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing ProgramPeter J Houghton, Christopher L Morton, Richard Gorlick, et al.
Carcinogenesis|December 11, 2012
Replication of GWAS-identified neuroblastoma risk loci strengthens the role of BARD1 and affirms the cumulative effect of genetic variations on disease susceptibilityMario Capasso, Sharon J Diskin, Francesca Totaro, et al.
Medical and Pediatric Oncology|July 24, 2001
Allelic deletion at chromosome bands 11q14-23 is common in neuroblastomaJ M Maris, C Guo, P S White, et al.
Pageof 46